Table 1.
Main characteristic of included trials
| First author | Year | Country | Phase | Regimen | Bevacizumab schedule | Mean age (B/C) | Total number | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| B | C | |||||||
| Kabbinavar BF | 2003 | USA | II | C: FU/LV | 5 or 10 mg/kg every two weeks | - | 35/33 | 36 |
| B: FU/LV plus Bevacizumab | ||||||||
| Hurwitz H | 2004 | UK | II | C: IFL plus Placebo | 5 mg/kg every two weeks | 59.5/59.2 | 402 | 411 |
| B: IFL plus Bevacizumab | ||||||||
| Kabbinavar FF | 2005 | USA | II | C: FU/LV plus Placebo | 5 mg/kg every two weeks | 71.3/70.7 | 104 | 105 |
| B: FU/LV plus Bevacizumab | ||||||||
| Saltz LB | 2008 | UK | III | C: FOLFOX-4 or XELOX plus placebo | 7.5 mg/kg every 3 weeks | 60.0 (18-86)/60 (18-83) | 699 | 701 |
| B: FOLFOX-4 or XELOX plus Bevacizumab | ||||||||
| Stathopoulos GP | 2010 | Greece | III | C: IFL | 7.5 mg/kg every 3 weeks | 67 (45-82)/62 (30-87) | 114 | 108 |
| B: IFL plus Bevacizumab | ||||||||
| Tebbutt NC | 2010 | Australia | III | C: Capecitabine | 7.5 mg/kg every 3 weeks | 67 (32-85)/69 (37-86) | 157 | 156 |
| B: Capecitabine plus Bevacizumab | ||||||||
| Guan ZZ | 2011 | China | III | C: mIFL | 5 mg/kg every two weeks | 53 (23-77)/50 (22-72) | 139 | 64 |
| B: mIFL plus Bevacizumab | ||||||||
| Zhang HM | 2012 | China | II | C: FOLFIRI | 5 mg/kg every two weeks | 52 (20-77) | 20 | 20 |
| B: FOLFIRI plus Bevacizumab | ||||||||
| Cunningham D | 2013 | UK | III | C: Capecitabine | 7.5 mg/kg every 3 weeks | 76 (70-87)/77 (70-87) | 140 | 140 |
| B: Capecitabine plus Bevacizumab | ||||||||
B, Bevacizumab-based group; C, control group FU/LV, fluorouracil and leucovorin. mIFL, modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion; FOLFOX, xaliplatin plus infusional 5-FU.